

NEW DEVELOPMENTS IN MULTIPLE MYELOMA

Madrid, Spain

Friday May 16 – Saturday May 17, 2008

Course Objective:

This course will provide the background for haematologists, oncologists and others involved in the treatment of multiple myeloma to understand the basic science and the clinical achievements in multiple myeloma therapy.

This is intended to be a practice oriented course, helping decision making processes for the clinician. Participants will have an opportunity to discuss patient case studies and interact with experts as well as receive updates on the latest data and advances in this field.

For this course CME accreditation (ACOE/AMA) application is pending.

Each participant will receive a certificate of attendance stating that he/she attended the entire course. The certificate of attendance will be distributed only at the end of the meeting, after a learning assessment test.

Target Audience:

Physicians and Other Healthcare Professionals

Official Language:

English



NEW DEVELOPMENTS IN MULTIPLE MYELOMA

MADRID, SPAIN

FRIDAY MAY 16 – SATURDAY MAY 17, 2008



This course is being supported by an unrestricted educational grant from Celgene and Novartis



NEW DEVELOPMENTS IN MULTIPLE MYELOMA



The new understanding of multiple myeloma has evolved from theory to practical clinical application. The initial successes promise to become very important for cancer patient care. There are many questions that will need evaluation, and the professional, patient and lay community is looking forward to these developments. We wish great success to this meeting, organized in collaboration with a great faculty and our two centers.

J. San Miguel & J.L. Harousseau

MADRID, SPAIN

FRIDAY MAY 16 – SATURDAY MAY 17, 2008

CHAIRMEN:

JESUS SAN MIGUEL and **JEAN-LUC HAROUSSEAU**

SCIENTIFIC COURSE COORDINATOR:

MATTI AAPRO

VENUE:

Hotel Meliá Castilla

Capitán Haya 43

28020 Madrid

Spain

FRIDAY, MAY 16, 2008

Registration opens at 10:00 am. Lunch buffet available from 12:00 Noon.

13.30–13.35 Welcome and Opening Words
J. San Miguel, J.L. Harousseau, M. Apro

13.35–14.05 **KEYNOTE PRESENTATION: Challenges and Opportunities in the Treatment of Multiple Myeloma – Looking into the Future.** *M. Attal*

SESSION I: Biology and Prognostic Indicators.
Chair: H. Avet-Loiseau

Each 15 minute presentation is preceded and followed by one interactive question using a keypad, followed by 10 minutes discussion.

14.05–14.25 Apoptosis and Development of Resistance in Multiple Myeloma.
G. Morgan

14.25–14.50 The Use of Cytogenetics for Defining Prognosis and Treatment in the Clinic. *H Avet-Loiseau*

14.50–15.15 New Prognostic Factors and Staging Systems in Multiple Myeloma.
M. Dimopoulos (tbc)

SESSION II: The Three Musketeers in Multiple Myeloma: Three Presentations on the Mechanisms of Action and Side-Effects of New Agents.
Chair: M. Apro

15.15–15.35 Lenalidomide (Revlimid®) [incl MOA]. *J. San Miguel*

15.35–15.50 Thalidomide [incl MOA]. *J.L. Harousseau*

15.50–16.10 Bortezomib (Velcade) [incl MOA]. *P. Sonneveld*

16.10–16.40 **Coffee Break**

INTERMEZZO

16.40–17.00 What Can We Expect from Current and Planned Clinical Trials?
T. Facon

SESSION III: Disease and Treatment Complications
Chair: J.L. Harousseau

15 minute presentations are preceded and followed by interactive questions using a keypad and followed by 10 minute discussion.

17.00–17.25 Bone Integrity in Multiple Myeloma. *E. Terpos*

17.25–17.50 Side-Effects Profiles of New Therapies. *A. Palumbo*

17.50–18.15 Management of Other Disease Complications. *M. Dimopoulos*

18.15 **Closure of the Day**

20.00 **Depart from the Hotel Lobby to Course Dinner**



SATURDAY MAY 17, 2008

SESSION IV: Stem Cell Transplantation.
Chair: J. San Miguel

10-15 minute presentations are preceded and followed by interactive questions using a keypad followed by a 5 minute group discussion.

08.30 – 08.50 The Role and Timing of Autologous Stem Cell Transplantation.
J.L. Harousseau

08.50 – 09.10 The Role and Timing of Allogeneic Stem Cell Transplantation.
N. Kröger

09.10 – 09.25 How to Modulate the GVHD and GVM Effects.
A. Perez-Simon

09.25 – 09.55 Panel Discussion: Early vs Late Transplantation & Best Options for Induction, Consolidation & Maintenance Therapy.
J. San Miguel, J.L. Harousseau, A. Perez-Simon, M. Boccadoro, N. Kröger

09.55 – 10.20 **Coffee Break**

SESSION V: Evaluating Systemic Treatment Options.
Chair: M. Boccadoro

10.20 – 10.40 What is Best for the Young Patient with Newly Diagnosed Disease?
M.V. Mateos

10.40 – 11.15 Optimal Management of Elderly or Frail Patients – Including Patient Case Discussion. *M. Boccadoro*

11.15 – 11.50 Treatment of Relapsed and Refractory Myeloma – Including Patient Case Discussion. *M. Attal*

11.50 – 12.30 **Panel Discussion: Proposed Treatment Algorithms.**
Moderator: J. San Miguel Panelists: All

11.50 – 12.10 First Line Multiple Myeloma Patients

12.10 – 12.30 Relapsed/Refractory Multiple Myeloma Patients

12.30 – 12.40 **Learning Assessments.** *Attendees to fill in their evaluation forms and answer 15 questions based on the course. Certificates will be given ONLY afterwards.*

12.40 - 14.20 **Lunch-buffet and Certificate Delivery**

FACULTY:

Matti S. Apro
Doyen IMO Clinique de Genolier
Genolier, Switzerland

Michel Attal
Hôpital Purpan
Toulouse, France


Hervé Avet-Loiseau
Centre Hospitalier
Universitaire Hôtel Dieu
Nantes, France

Mario Boccadoro
University of Torino
Torino, Italy

Meletios A. Dimopoulos
University of Athens School of Medicine
Athens, Greece

Thierry Facon
Centre Hospitalier Universitaire
Lille, France

Jean-Luc Harousseau (Chairman)
University Hospital Nantes
Nantes, France



Nicolaus Kröger
University Hospital
Hamburg-Oppendorf
Hamburg, Germany

Marivi Mateos
Univerity of Salamanca
Salamanca, Spain

Gareth Morgan
The Royal Marsden Hospital
Sutton, Surrey
United Kingdom

Antonio Palumbo
University of Torino
Turino, Italy

José A. Pérez-Simón
Hospital Clinic University
Salamanca, Spain

Jesus F. San-Miguel (Chairman)
Hospital Universitario de
Salamanca and Centro de
Investigacion del Cancer (CIC)
University of Salamanca
Salamanca, Spain

Pieter Sonneveld
Erasmus Medical Center Rotterdam
Rotterdam, The Netherlands

Evangelos Terpos
Imperial College
London, United Kingdom